ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/IGF1R
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/IGF1R
3
trial(s) found.
NCT03746431
Radonc
Phase 1 / Phase 2
Recruiting
A Phase 1 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid Tumours (
FPX-01-01
)
FPI-1175
FPI-1547
IGF1R-radionucleotide conjugate
cancer therapy
radioconjugate therapy
radiopharmaceutics
+ IGF1R-radionucleotide conjugate
Breast cancer
Carcinoma
Cervical cancer
Endometrial cancer
HER2-negative breast cancer
Head and neck squamous cell carcinoma
Ovarian cancer
Solid tumour
Triple-negative breast cancer
Uveal melanoma
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (COMPLETED)
NCT02645149
Advanced
Phase 2
Recruiting
Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (
MatchMel
)
ALK/ROS1/IGF1R inhibitor
ALK inhibitor
ALK inhibitor,second generation
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
Ceritinib
IGF1R inhibitor
MEK inhibitor
ROS1 inhibitor
Ribociclib
Trametinib
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,IGF1R-targeting
cancer therapy,MEK-targeting
cancer therapy,ROS1-targeting
+ ALK/ROS1/IGF1R inhibitor
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
ACTRN12616001187437
Advanced
Phase 2
Not recruiting
Molecular profiling to identify patients with BRAF/NRAS wild type melanoma and the proportion of these patients that undergo matched targeted therapy as a result of extended molecular testing. (
MatchMel
)
ALK/ROS1/IGF1R inhibitor
ALK inhibitor
ALK inhibitor,first generation
ALK inhibitor,second generation
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,first generation
BCR-ABL1 inhibitor,second generation
Bortezomib
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
Cabozantinib
Ceritinib
Crizotinib
Dasatinib
EGFR inhibitor
EGFR inhibitor,first generation
EGFR inhibitor,type II
ERBB2 inhibitor
ERBB2 inhibitor,first generation
Erlotinib
Everolimus
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
FLT3 inhibitor
Gefitinib
HDAC inhibitor
IGF1R inhibitor
Imatinib
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,ATP-competitive
KIT inhibitor,first generation
Lapatinib
MEK inhibitor
MET inhibitor
MET inhibitor,type 1
MET inhibitor,type 2
Nilotinib
Olaparib
PARP inhibitor
PDGFRA inhibitor
PDGFR inhibitor
Palbociclib
Pazopanib
RAF inhibitor
RET inhibitor
ROS1 inhibitor
Ramucirumab
Regorafenib
SRC inhibitor
Sorafenib
Sunitinib
Trametinib
VEGFR2 inhibitor
VEGFR inhibitor
Vorinostat
YES1 inhibitor
anti-VEGFR2 monoclonal antibody
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,AXL-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CRAF-targeting
cancer therapy,EGFR-targeting
cancer therapy,ERBB2-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,FLT3-targeting
cancer therapy,HDAC-targeting
cancer therapy,IGF1R-targeting
cancer therapy,KIT-targeting
cancer therapy,MEK-targeting
cancer therapy,MET-targeting
cancer therapy,PARP-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,RAF-targeting
cancer therapy,RET-targeting
cancer therapy,ROS1-targeting
cancer therapy,SRC-targeting
cancer therapy,VEGFR-targeting
cancer therapy,VEGFR2-targeting
cancer therapy,YES1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,proteasome-targeting
immuno-oncology therapy,VEGFR2-targeting
mTORC1 inhibitor
mTOR inhibitor
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
proteasome inhibitor
+ ALK/ROS1/IGF1R inhibitor
Melanoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (2)
Not recruiting (1)
Recruitment Country and State
NSW (2)
VIC (1)
Phase
Phase 1 / Phase 2 (1)
Phase 2 (2)
Trial Type
Advanced (2)
Radonc (1)
Cancer Therapy Class
ALK
67%
CDK4
67%
CDK6
67%
IGF1R
67%
MEK
67%
ROS1
67%
AXL
33%
BCR-ABL1
33%
CRAF
33%
EGFR
33%
ERBB2
33%
FGFR1
33%
FGFR1/2/3
33%
FGFR2
33%
FGFR3
33%
FGFR4
33%
FLT3
33%
HDAC
33%
KIT
33%
MET
33%
PARP
33%
PDGFR
33%
PDGFRA
33%
RAF
33%
RET
33%
SRC
33%
VEGFR
33%
VEGFR2
33%
YES1
33%
mTOR
33%
mTORC1
33%
proteasome
33%
Facility
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (2)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
Cancer Type
Cancer
Melanoma
Solid tumour
Breast adenocarcinoma
Breast cancer
Carcinoma
Cervical cancer
Endometrial cancer
Gynaecological cancer
HER2-negative breast cancer
HPV-related cancer
HPV16-positive cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Ovarian cancer
Triple-negative breast cancer
Uveal melanoma
Viral-related cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy